1 / 21

Innovotech Inc.

Innovotech Inc. Annual General Meeting 20 April 2010 Edmonton, Alberta. Innovotech Inc. A G E N D A Welcome Formal Administrative Business Adjournment of AGM Business Update Q&A. Innovotech Inc. Formal Administrative Business. Innovotech Inc. Election of Directors: Dr Lorne Babiuk

glenna
Download Presentation

Innovotech Inc.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Innovotech Inc. Annual General Meeting 20 April 2010 Edmonton, Alberta

  2. Innovotech Inc. A G E N D A • Welcome • Formal Administrative Business • Adjournment of AGM • Business Update • Q&A

  3. Innovotech Inc. Formal Administrative Business

  4. Innovotech Inc. Election of Directors: • Dr Lorne Babiuk • Mr Kerry Brown • Mr Bruce D. Hirsche Q.C. • Dr Wolfgang H. Muhs • Mr John Pinsent • Dr Gerard Tertzakian • Dr James Timourian

  5. Innovotech Business Update

  6. 2009 – Moving to Market Objectives & Performance in 2009

  7. 2009 Financial Results

  8. bioFILM PA - Objectives bioFILM PA goals for 2009: Revenue Expand through commercial partner Path: Canada: Maintain current plan USA: “Research Use Only” through Partner Convert to dry panel

  9. bioFILM PA -Stakeholders Alberta Health Payer Laboratory User IOT Patients Recipient Doctors Decision-maker

  10. bioFILM - Market potential Market - bioFILM PA: Canada US World Cystic Fibrosis $2.4M $24M $50M Ventilator Associated Pneumonia $35M $70M Other (burns, wounds) tbd Market – bioFILM SA: Canada US World Catheters Dialysis Other (CF, VAP) Total >$150M

  11. bioFILM PA – 2010 Objectives Revenue in Canada Published paper Health economic evaluation Enter other markets US through private diagnostic laboratory Israel SA development Low cost and quick development Augments PA disease use (CF and VAP)

  12. Agress – Objectives Agress goals for 2009: Regulatory approval for pulses Commercial agreement Path: Maintain current Co interest Potential reg filing for Fire Blight Develop AUS R&D Launch in N America for pulses post-09

  13. Agress – PMRA (Canada) Current situation: Innovotech denied waiver claims Asked to re-submit with expedited review for approved components Fees partially refunded 4 crops, 13 diseases, 1 use pattern New submission: Determine EPA stance Use Syngenta regulatory team Evaluate current consultants 8 crops, 25 diseases, 2 use patterns

  14. Agress – Syngenta partnership Agress to be used as “anti-bacterial” component of many products Syngenta press release on partnership Post-trade show orders of 1.5kg of Agress Syngenta (US) interest in Pithium data in corn

  15. Agress – 2010 Objectives Expand product claims Crop, Disease and Use pattern Incorporate Syngenta trials Remove regulatory hurdles Meet with agencies Draw on external scientific expertise Maintain flexibility with other companies

  16. Silver Periodate opportunity Unique properties Patentable discovery Interest of medical device and agriculture companies Assembly of internal team

  17. 2010 – Objectives Our goals for 2010: bioFILM PA™ Agress R&D Contract Research Revenue Enter US market Expand claims Remove regulatory hurdles Product candidate from Silver periodate Develop bioFILM SA Photo-dynamic approval as sanitizer Revenue growth

  18. Ken Boutilier, President Innovotech Inc. ken.boutilier@innovotech.ca Ph: 780-448-0585 ext 221 Fax: 780-424-0941 Contact Information

  19. 2008 Summary - Agress™ Factors: Treatment is based on disease pressure  Crop guarantees by sellers increases treatments  A suitable antibacterial is lacking  Formulations are as important as “actives”  Agress will be in a combination with other agents Seed & Foliar All crops World $20B+ Seed Treatment, All crops North America $120M Seed Treatment, Pulse crops North America $3-5M

  20. Agress – Market Potential Markets Agress is price competitive in all markets!

More Related